* To replay the media content and watch again, please refresh your screen

In this interactive patient case, you'll meet a 50-year-old man diagnosed with clear cell renal cell carcinoma (ccRCC).  As you work through the case, you'll consider suitable first-line options, how to define progression in a long-term durable response, and how to know when it's the right time to switch to second-line therapy.

 

Along the way, you'll answer questions at key points and engage with clickable resources to deepen your understanding of: 

  • The efficacy and safety profiles of targeted and immunotherapies for advanced RCC 
  • How to implement targeted and immunotherapies into the treatment strategy of patients with advanced RCC, and the optimal sequencing of treatments 
  • How to treat those patients who achieve prolonged responses on 1L therapy

 

Clinical Takeaways

  • Clinical guidelines recommend a frontline combination with either IO-IO or IO-TKI for IMDC intermediate/poor risk patients with advanced ccRCC 
  • Patients who achieve a prolonged response on first-line therapy can continue on this treatment until clinical and radiographical disease progression occurs  
  • To ensure optimal sequencing of treatments, patients should receive a VEGF-targeted therapy that has not been used previously in combination with immunotherapy

 

This video has been sponsored by Eisai Europe Limited (“Eisai”). Eisai has had no input on the educational content of or speakers involved in this video.

Educational objectives

  • Understand and be able to differentiate the efficacy and safety profiles of targeted and immunotherapies for advanced RCC 
  • Recognise how to implement targeted and immunotherapies into the treatment strategy of patients with advanced RCC, and understand the optimal sequencing of treatments 
  • Explore the treatment options for those patients who achieve prolonged complete responses 

Michael Staehler is the Head of the Interdisciplinary Centre for Renal Tumours at the Ludwig-Maximilians University of Munich, Germany.

 

He is a member of the Renal Cancer Workgroup of the German Cancer Society. He also serves as a member of the German Guideline Committee on Renal Cancer.

 

Following medical qualification at University of Munich Medical School and gaining experience in general, vascular and thoracic surgery at the University of Regensburg, the University of California in San Francisco and his training in Urology at the Free University, Berlin, he was awarded a PhD for his work on renal cancer at the University of Munich.

 

After joining the Department of Urology, he was appointed Consultant Urologist at Grosshadern Clinics and founded the Interdisciplinary Centre on Renal Tumours in Germany. He is also Head of the Urological Oncology Service for Advanced Genitourinary Cancer and Kidney surgery.

 

Professor Staehler’s main research interest has been the development of novel therapeutics in renal cell carcinoma, particularly in the area of radiation therapy, surgical therapy and novel targeted agents. He is a Medical Advisor to the German Kidney Cancer Association.

 

He is on the editorial board of several journals and Professor Staehler has published more than 220 articles on renal cancer and co-authored six textbooks.

Prof. Michael Staehler has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Consultant: Apogepha, Astellas, Aveo, Bayer, BMS, Eisai, Exelixis, EUSAPharm, GlaxoSmithKline, Ipsen, Jansen, MSD, Novartis, Oncorena, Pelloton, Pfizer, Recordati, Roche

 

Honoraria: Apogepha, Astellas, Aveo, Bayer, BMS, Eisai, EUSAPharm, Exelixis, GlaxoSmithKline, Ipsen, Johnson & Johnson, MSD, Novartis, Pelloton, Pfizer, Recordati

 

Research Funding: AstraZeneca, AVEO, Bayer, BMS, Eisai, Exelixis, GlaxoSmithKline, Immatics, Ipsen, Novartis, Pfizer, Roche/Genentech, Wilex

Programme summary
  • clock Duration 15 MIN
  • clock Language(s) flag
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Eisai Europe Limited.
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Medical Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts

Other programmes of interest

Video
Oncology 
The evolving role of liquid biopsy in biomarker testing

Clinical application of liquid biopsy, and how it applies to NSCLC, breast and colorectal cancer

Experts
Assoc. Prof. Umberto Malapelle
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jul 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Other

Episode

1

of 1

episode
Oncology 
Overcoming pre-analytical phase challenges in gastric, prostate and lung cancer

Medical experts make recommendations for best practice

Experts
Dr Alexander Wyatt, Prof. Frédéric Bibeau
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Conference update
Oncology 
Oncogene-addicted NSCLC: Highlights from ASCO 2024

The latest non-small cell lung cancer data presented at ASCO

Experts
Prof. Nicolas Girard
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Upper lower GI cancer update ASCO 2024 Conference update
Oncology 
Upper and lower GI cancer update from ASCO 2024

GI oncologists review the latest data presented at ASCO 2024

Experts
Dr Samuel J Klempner, Dr Elizabeth Smyth, Prof. Jenny Seligmann, Dr Dominik Modest
  • clock 8 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Experts Knowledge Share Video
Oncology Hemato-oncology 
Optimising the management of multiple myeloma in the early relapsed/refractory setting (RRMM)

Medical experts discuss the latest learnings from clinical practice

Experts
Prof. Aurore Perrot, Prof. Hermann Einsele, Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Joshua Richter
  • download Downloadable
    Resources
  • clock 76 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline Oncology.
Conference update

Episode

1

of 4

episode
Oncology 
ASCO 2024 lung cancer highlights

A conference update on lung cancer clinical trial data from ASCO

Experts
Prof. Mark Socinski
  • clock 4 MIN
  • calendar Jun 2024